Key result
Identifying biomarkers in MINOCA aims to improve diagnosis, individualize treatment, and better predict outcomes.
Why the study?
Definitive diagnosis of MINOCA remains elusive and the lack of comprehensive understanding of its pathophysiology complicates clinical management.
Biomarkers may play a crucial role in improving the diagnosis, individualized treatment, and outcome prediction for patients with MINOCA.
Biomarker efforts in MINOCA remain exploratory; leaves open prospective validation before any diagnostic or therapeutic role.
Myocardial infarction in the absence of obstructive coronary artery disease (MINOCA) is an important subtype of myocardial infarction. Although comprising less than 50% stenosis in the main epicardial coronary arteries, it constitutes a severe health risk. A variety of approaches have been recommended, but definitive diagnosis remains elusive. In addition, the lack of a comprehensive understanding of underlying pathophysiology makes clinical management difficult and unpredictable. This review highlights ongoing efforts to identify relevant biomarkers in MINOCA to improve diagnosis, individualize treatment and better predict outcomes.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2023) conducted a review in Myocardial infarction in the absence of obstructive coronary artery disease (MINOCA). Biomarkers was evaluated. Ongoing efforts to identify relevant biomarkers in MINOCA aim to improve diagnosis, individualize treatment, and better predict outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: